KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to -$9.9 million.

  • Neogenomics' Net Income towards Common Stockholders rose 3551.94% to -$9.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$108.0 million, marking a year-over-year decrease of 3721.64%. This contributed to the annual value of -$108.0 million for FY2025, which is 3721.64% down from last year.
  • According to the latest figures from Q4 2025, Neogenomics' Net Income towards Common Stockholders is -$9.9 million, which was up 3551.94% from -$27.1 million recorded in Q3 2025.
  • In the past 5 years, Neogenomics' Net Income towards Common Stockholders registered a high of $77.4 million during Q2 2021, and its lowest value of -$49.4 million during Q1 2022.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$23.5 million (2022), whereas its average is -$21.3 million.
  • The largest annual percentage gain for Neogenomics' Net Income towards Common Stockholders in the last 5 years was 123459.85% (2021), contrasted with its biggest fall of 54898.5% (2021).
  • Over the past 5 years, Neogenomics' Net Income towards Common Stockholders (Quarter) stood at -$41.8 million in 2021, then surged by 45.67% to -$22.7 million in 2022, then skyrocketed by 36.85% to -$14.3 million in 2023, then fell by 6.97% to -$15.3 million in 2024, then skyrocketed by 35.52% to -$9.9 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$9.9 million for Q4 2025, versus -$27.1 million for Q3 2025 and -$45.1 million for Q2 2025.